29 June, 2017
Kirkland & Ellis is advising a consortium led by Mr. Weidong Yin, the chairman, president and chief executive officer of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac”), a leading provider of biopharmaceutical products in China, and SAIF Partners, in connection with the proposed acquisition of Sinovac. The definitive agreement, which valued the transaction at approximately US$401.8 million, was announced on June 26, 2017.
The Kirkland team is led by Hong Kong corporate partners David Zhang and Henry Yin.
